131 related articles for article (PubMed ID: 17117591)
1. Drug evaluation: apratastat, a novel TACE/MMP inhibitor for rheumatoid arthritis.
Thabet MM; Huizinga TW
Curr Opin Investig Drugs; 2006 Nov; 7(11):1014-9. PubMed ID: 17117591
[TBL] [Abstract][Full Text] [Related]
2. Identification and characterization of 4-[[4-(2-butynyloxy)phenyl]sulfonyl]-N-hydroxy-2,2-dimethyl-(3S)thiomorpholinecarboxamide (TMI-1), a novel dual tumor necrosis factor-alpha-converting enzyme/matrix metalloprotease inhibitor for the treatment of rheumatoid arthritis.
Zhang Y; Xu J; Levin J; Hegen M; Li G; Robertshaw H; Brennan F; Cummons T; Clarke D; Vansell N; Nickerson-Nutter C; Barone D; Mohler K; Black R; Skotnicki J; Gibbons J; Feldmann M; Frost P; Larsen G; Lin LL
J Pharmacol Exp Ther; 2004 Apr; 309(1):348-55. PubMed ID: 14718605
[TBL] [Abstract][Full Text] [Related]
3. Drug insight: tumor necrosis factor-converting enzyme as a pharmaceutical target for rheumatoid arthritis.
Moss ML; Sklair-Tavron L; Nudelman R
Nat Clin Pract Rheumatol; 2008 Jun; 4(6):300-9. PubMed ID: 18414459
[TBL] [Abstract][Full Text] [Related]
4. Characterization of (2R, 3S)-2-([[4-(2-butynyloxy)phenyl]sulfonyl]amino)-N,3-dihydroxybutanamide, a potent and selective inhibitor of TNF-alpha converting enzyme.
Zhang Y; Hegen M; Xu J; Keith JC; Jin G; Du X; Cummons T; Sheppard BJ; Sun L; Zhu Y; Rao VR; Wang Q; Xu W; Cowling R; Nickerson-Nutter CL; Gibbons J; Skotnicki J; Lin LL; Levin J
Int Immunopharmacol; 2004 Dec; 4(14):1845-57. PubMed ID: 15531300
[TBL] [Abstract][Full Text] [Related]
5. Design strategies for the identification of MMP-13 and Tace inhibitors.
Skotnicki JS; DiGrandi MJ; Levin JI
Curr Opin Drug Discov Devel; 2003 Sep; 6(5):742-59. PubMed ID: 14579524
[TBL] [Abstract][Full Text] [Related]
6. Acetylenic TACE inhibitors. Part 3: Thiomorpholine sulfonamide hydroxamates.
Levin JI; Chen JM; Laakso LM; Du M; Schmid J; Xu W; Cummons T; Xu J; Jin G; Barone D; Skotnicki JS
Bioorg Med Chem Lett; 2006 Mar; 16(6):1605-9. PubMed ID: 16426848
[TBL] [Abstract][Full Text] [Related]
7. Novel TNF-α converting enzyme (TACE) inhibitors as potential treatment for inflammatory diseases.
Girijavallabhan VM; Chen L; Dai C; Feltz RJ; Firmansjah L; Li D; Kim SH; Kozlowski JA; Lavey BJ; Kosinski A; Piwinski JJ; Popovici-Muller J; Rizvi R; Rosner KE; Shankar BB; Shih NY; Siddiqui MA; Tong L; Wong MK; Yang DY; Yang L; Yu W; Zhou G; Guo Z; Orth P; Madison V; Bian H; Lundell D; Niu X; Shah H; Sun J; Umland S
Bioorg Med Chem Lett; 2010 Dec; 20(24):7283-7. PubMed ID: 21106451
[TBL] [Abstract][Full Text] [Related]
8. Current perspective of TACE inhibitors: a review.
DasGupta S; Murumkar PR; Giridhar R; Yadav MR
Bioorg Med Chem; 2009 Jan; 17(2):444-59. PubMed ID: 19095454
[TBL] [Abstract][Full Text] [Related]
9. The evaluation of inhibitive effectiveness of the tumour necrosis factor-α converting enzyme selective inhibitors by HPLC.
Zhao Y; Yu J; Gu J; Huang W
J Enzyme Inhib Med Chem; 2011 Apr; 26(2):181-7. PubMed ID: 21406033
[TBL] [Abstract][Full Text] [Related]
10. Definition of peptide inhibitors from a synthetic peptide library by targeting gelatinase B/matrix metalloproteinase-9 (MMP-9) and TNF-α converting enzyme (TACE/ADAM-17).
Qiu Z; Yan M; Li Q; Liu D; Van den Steen PE; Wang M; Opdenakker G; Hu J
J Enzyme Inhib Med Chem; 2012 Aug; 27(4):533-40. PubMed ID: 21827363
[TBL] [Abstract][Full Text] [Related]
11. Novel TACE inhibitors in drug discovery: a review of patented compounds.
Murumkar PR; DasGupta S; Chandani SR; Giridhar R; Yadav MR
Expert Opin Ther Pat; 2010 Jan; 20(1):31-57. PubMed ID: 20021284
[TBL] [Abstract][Full Text] [Related]
12. Novel thiol-based TACE inhibitors: rational design, synthesis, and SAR of thiol-containing aryl sulfonamides.
Govinda Rao B; Bandarage UK; Wang T; Come JH; Perola E; Wei Y; Tian SK; Saunders JO
Bioorg Med Chem Lett; 2007 Apr; 17(8):2250-3. PubMed ID: 17289381
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and SAR of diazepine and thiazepine TACE and MMP inhibitors.
Zask A; Kaplan J; Du X; MacEwan G; Sandanayaka V; Eudy N; Levin J; Jin G; Xu J; Cummons T; Barone D; Ayral-Kaloustian S; Skotnicki J
Bioorg Med Chem Lett; 2005 Mar; 15(6):1641-5. PubMed ID: 15745814
[TBL] [Abstract][Full Text] [Related]
14. Potent, exceptionally selective, orally bioavailable inhibitors of TNF-alpha Converting Enzyme (TACE): novel 2-substituted-1H-benzo[d]imidazol-1-yl)methyl)benzamide P1' substituents.
Ott GR; Asakawa N; Lu Z; Anand R; Liu RQ; Covington MB; Vaddi K; Qian M; Newton RC; Christ DD; Trzaskos JM; Duan JJ
Bioorg Med Chem Lett; 2008 Mar; 18(5):1577-82. PubMed ID: 18242982
[TBL] [Abstract][Full Text] [Related]
15. Inflammation 2005 - Seventh World Congress. Highlights II.
Enefer S
IDrugs; 2005 Oct; 8(10):791-2. PubMed ID: 16254792
[No Abstract] [Full Text] [Related]
16. Drug evaluation: VX-702, a MAP kinase inhibitor for rheumatoid arthritis and acute coronary syndrome.
Ding C
Curr Opin Investig Drugs; 2006 Nov; 7(11):1020-5. PubMed ID: 17117592
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetic-pharmacodynamic modeling of apratastat: a population-based approach.
Shu C; Zhou H; Afsharvand M; Duan L; Zhang H; Noveck R; Raible D
J Clin Pharmacol; 2011 Apr; 51(4):472-81. PubMed ID: 21059888
[TBL] [Abstract][Full Text] [Related]
18. Blockade of tumor necrosis factor-alpha-converting enzyme improves experimental small intestinal damage by decreasing matrix metalloproteinase-3 production in rats.
Matsumoto H; Koga H; Iida M; Tarumi K; Fujita M; Haruma K
Scand J Gastroenterol; 2006 Nov; 41(11):1320-9. PubMed ID: 17060126
[TBL] [Abstract][Full Text] [Related]
19. Structure-based design of TACE selective inhibitors: manipulations in the S1'-S3' pocket.
Huang A; Joseph-McCarthy D; Lovering F; Sun L; Wang W; Xu W; Zhu Y; Cui J; Zhang Y; Levin JI
Bioorg Med Chem; 2007 Sep; 15(18):6170-81. PubMed ID: 17606376
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics and pharmacodynamics of DPC 333 ((2R)-2-((3R)-3-amino-3{4-[2-methyl-4-quinolinyl) methoxy] phenyl}-2-oxopyrrolidinyl)-N-hydroxy-4-methylpentanamide)), a potent and selective inhibitor of tumor necrosis factor alpha-converting enzyme in rodents, dogs, chimpanzees, and humans.
Qian M; Bai SA; Brogdon B; Wu JT; Liu RQ; Covington MB; Vaddi K; Newton RC; Fossler MJ; Garner CE; Deng Y; Maduskuie T; Trzaskos J; Duan JJ; Decicco CP; Christ DD
Drug Metab Dispos; 2007 Oct; 35(10):1916-25. PubMed ID: 17656469
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
